Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month High at $28.08

Rapport Therapeutics (NASDAQ:RAPP)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $28.08 and last traded at $26.42, with a volume of 3527 shares traded. The stock had previously closed at $27.57.

Analysts Set New Price Targets

RAPP has been the subject of several research reports. Jefferies Financial Group began coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target for the company. Stifel Nicolaus started coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective for the company. Finally, TD Cowen began coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating for the company.

Rapport Therapeutics Trading Down 2.8 %

Insider Activity

In related news, Director James Healy bought 44,032 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was purchased at an average cost of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the acquisition, the director now owns 40,851 shares in the company, valued at $1,001,666.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.